8
Participants
Start Date
September 10, 2021
Primary Completion Date
July 20, 2022
Study Completion Date
July 20, 2022
3SM2-G-CRM197 with squalene adjuvant
Immune challenge agent
NIHR Imperial Clinical Research Facility, London
Collaborators (1)
Minka Therapeutics
UNKNOWN
ANRS, Emerging Infectious Diseases
OTHER_GOV
Imperial College London
OTHER